ArticleScientific reports2026
Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The clinical activity of tyrosine kinase inhibitors (TKI) varies across cancer types of cancers bearing similar receptor tyrosine kinase (RTK) mutations. Analyzing public databases, we tested the hypothesis that RTK function in normal cell could predict for TKI activity in the corresponding cancer. Classes of alterations for 16 RTK (missense mutations, amplifications, translocations) were analyzed in 17 different solid tumors, and tested as biomarkers of TKI efficacy in pivotal trials. Single agent TKI activity was minimal in cancers bearing RTK amplification. TKI activity was found correlated with the type RTK mutation but also to the functional role of the RTK in normal cell. A missense mutation of an RTK correlated with TKI efficacy when the RTK exerts an important function in the corresponding normal cell. Conversely, translocations were tissue-agnostic biomarkers, independent of RTK function in normal cells. These results provide guidance for the selection of cancers for development of novel targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.